Navigation Links
Anthrax inhibitors identified by Burnham team

lone.

"This represents a significant advance in developing a possible emergency treatment for anthrax," said Dr. Pellecchia. "We are working on refining the chemical structure of the compound with the goal of achieving an even more potent and selective drug that should exhibit a higher degree of protection against anthrax."

This research was supported by grants from the National Institute of Allergy and Infectious Diseases, from the National Institutes of Health.

Coauthors on this study include:

Martino Forino, Sherida Johnson, Tian Y. Wong, Dimitri V. Rozanov, Alexei Y. Savinov, Wei Li, Roberto Fattorusso, Barbara Becattini, and Dawoon Jung, from The Burnham Institute.
Robert Liddington, Ph.D., Acting Director, Center for Infectious and Inflammatory Diseases at The Burnham Institute;
Alex Strongin, Ph.D., Professor, Cell Adhesion/Extracellular Matrix Program, The Burnham Institute;
Jeffrey Smith, Ph.D., Professor, and Director of the Center for Proteolytic Pathways at The Burnham Institute;
Ruben A. Abagyan, Ph.D., Professor, and Andrew J. Orry, Molecular Biology Department at The Scripps Research Institute;
Ken Alibek, Ph.D., National Center for Biodefense, George Mason University, Fairfax, Virginia.

###

The Burnham Institute, founded in 1976, is an independent not-for-profit biomedical research institution dedicated to advancing the frontiers of scientific knowledge and providing the foundation for tomorrow's medical therapies. The Institute is home to three major centers: the original Cancer Center, the Del E. Webb Neuroscience and Aging Center established in 1999, and the Infectious and Inflammatory Disease Center dedicated in 2004. Since 1981, the Institute's Cancer Center has earned the prestigious designation as a Non-comprehensive Cancer Center by the National Cancer Institute. Discoveries by Burnham scientists have contributed to the development of new drugs for Alzheimer's disea
'"/>

Source:Burnham Institute


Page: 1 2 3

Related biology news :

1. Study Models Impact Of Anthrax Vaccine
2. Anthrax test, developed by army and CDC, receives FDA approval
3. Anthrax stops body from fighting back, study shows
4. Anthrax spores may survive water treatment
5. Anthrax inhibitor counteracts toxin, may lead to new therapeutics
6. Anthrax attack posed greater potential threat than thought
7. Anthrax paralyzes immune cells with lethal toxin, UF research shows
8. Protease inhibitors reach beyond HIV
9. Enzyme inhibitors block replication of SARS virus
10. Sweet water taste paradoxically predicts sweet taste inhibitors
11. COX-2 inhibitors significantly reduce risk of cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anthrax inhibitors identified Burnham team

(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... described fossil whales---a pregnant female and a male of the ... insights into how whales made the transition from land to ... 2000 and 2004 and studied at the University of Michigan, ... online journal PLoS . U-M paleontologist Philip Gingerich, ...
... In 2005, a woman who had trouble sleeping asked ... sleep disorders specialist at the Mayo Clinic campus in ... interrupts sleep because of unpleasant sensations in the legs ... relieved by movement. Restless legs syndrome affects ...
... State University already have shown that gardening can offer enough ... In research to be published in February in the journal ... health benefits of gardening is keeping older hands strong and ... older adults who are gardeners have better hand strength and ...
Cached Biology News:Early whales gave birth on land, fossil find reveals 2Mayo Clinic researchers suspect a novel gene is causing restless legs syndrome in a large family 2Gardening gives older adults benefits like hand strength and self-esteem 2
(Date:5/29/2015)... N.C. , May 29, 2015 ... affairs function into roles involving clinical development, regulatory ... its responsibilities have grown, Medical Affairs has faced ... as a global group. And while its importance ... it challenging to identify strong performance metrics to ...
(Date:5/29/2015)... , May 29, 2015 In recent ... the availability of Big Data that can generate valuable ... come with utilizing Big Data have caused the biopharmaceutical ... other industries. According to a recent ... participants already have a Big Data team or function ...
(Date:5/29/2015)... , May 29, 2015 ... company, today announces that an abstract on the latest ... inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, ... BerGenBio, has been published in conjunction with the 2015 ... Chicago , May 29 - June ...
(Date:5/29/2015)... 2015 GeneWEAVE, Inc ., ... announced that initial feasibility data supporting the use ... susceptibility testing from positive blood cultures will be ... 2015 in New Orleans, LA. The Company’s Smarticles™ ... that can quickly detect bacteria and assess antibiotic ...
Breaking Biology Technology:Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3
... Corp.,(TSX, FSE: "HBP") today announced financial results for the first quarter,of ... - Subsequent to the first quarter, the Company ... of common shares, subject to closing, ... Segal remaining the Company,s Chief Executive ...
... two important surgical tools: Baxter,s ... human thrombin and Pfizer,s GELFOAM, ... announced the Food and Drug Administration approval of,GELFOAM(R) Plus ... Plus is the only available hemostasis kit that contains,Pfizer,s ...
... Lilly to Acquire Exclusive Rights to Novel Late-Stage Molecule for ... ... 17 ,Eli Lilly and Company (NYSE: LLY ) and ... have entered into a licensing and,development agreement granting Lilly exclusive ...
Cached Biology Technology:Helix BioPharma announces Q1 2008 financial results 2Helix BioPharma announces Q1 2008 financial results 3Helix BioPharma announces Q1 2008 financial results 4Helix BioPharma announces Q1 2008 financial results 5Helix BioPharma announces Q1 2008 financial results 6Helix BioPharma announces Q1 2008 financial results 7Helix BioPharma announces Q1 2008 financial results 8Helix BioPharma announces Q1 2008 financial results 9Helix BioPharma announces Q1 2008 financial results 10Helix BioPharma announces Q1 2008 financial results 11Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 2Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 3Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 4Lilly and BioMS Medical Announce Global Licensing and Development Agreement 2Lilly and BioMS Medical Announce Global Licensing and Development Agreement 3Lilly and BioMS Medical Announce Global Licensing and Development Agreement 4Lilly and BioMS Medical Announce Global Licensing and Development Agreement 5Lilly and BioMS Medical Announce Global Licensing and Development Agreement 6